Tempest Therapeutics Inc.
(TPST)
undefined
undefined%
At close: undefined
0.95
-0.59%
After-hours Jan 03, 2025, 05:56 PM EST
Company Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer.
The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors.
It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors.
The company was founded in 2011 and is headquartered in South San Francisco, California.
Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Tempest Therapeutics Inc.
| Country | United States |
| IPO Date | Nov 12, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Stephen R. Brady J.D., LLM |
Contact Details
Address: 7000 Shoreline Court South San Francisco, California United States | |
| Website | https://www.tempesttx.com |
Stock Details
| Ticker Symbol | TPST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001544227 |
| CUSIP Number | 87978U108 |
| ISIN Number | US87978U1088 |
| Employer ID | 45-1472564 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen R. Brady J.D., LLM | Chief Executive Officer, President & Director |
| Dr. Samuel Whiting M.D., Ph.D. | Executive Vice President & Chief Medical Officer |
| Lindsay Young | Head of Human Resources |
| Nicholas Maestas | Vice President of Strategy & Finance and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 31, 2024 | 8-K | Current Report |
| Dec 06, 2024 | 8-K | Current Report |
| Nov 12, 2024 | DEF 14A | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 29, 2024 | PRE 14A | Filing |
| Oct 10, 2024 | 8-A12B/A | [Amend] Filing |
| Oct 10, 2024 | 8-K | Current Report |
| Aug 12, 2024 | SC 13D/A | [Amend] Filing |
| Aug 12, 2024 | 4 | Filing |